Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desipramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 0.94 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.94 |
| ▸ | HTR2A | P28223 | 4/20 | 0.94 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.94 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.94 |
| ▸ | DRD2 | P14416 | 4/20 | 0.94 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.94 |
| ▸ | HRH1 | P35367 | 4/20 | 0.94 |
| ▸ | DRD3 | P35462 | 4/20 | 0.94 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.94 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.94 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.94 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.94 |
| ▸ | HTR2C | P28335 | 3/20 | 0.94 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.94 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.94 |
| ▸ | HTR2B | P41595 | 3/20 | 0.94 |
| ▸ | MTOR | P42345 | 3/20 | 0.94 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desipramine SCHEMBL29379525 | 0.97 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP3A4HTR2ACHRM2 | |
| Desipramine SCHEMBL34384 | 0.97 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP3A4HTR2ACHRM2 | |
| Desipramine SCHEMBL5072939 | 0.97 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP3A4HTR2ACHRM2 | |
| Desipramine SCHEMBL41992 | 0.95 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP3A4HTR2ACHRM2 | |
| Desipramine SCHEMBL2944786 | 0.95 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP3A4HTR2ACHRM2 | |
| Desipramine SCHEMBL29364790 | 0.95 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP3A4HTR2ACHRM2 | |
| Desipramine SCHEMBL5501781 | 0.95 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP3A4HTR2ACHRM2 | |
| Desipramine SCHEMBL29085912 | 0.95 | SLC6A4 (0.97) | SLC6A4SLC6A2CYP3A4HTR2ACHRM2 | |
| Desipramine SCHEMBL27517227 | 0.88 | SLC6A4 (0.83) | SLC6A4SLC6A2CYP3A4HTR2ACHRM2 | |
| Desipramine SCHEMBL28105338 | 0.88 | SLC6A4 (0.83) | SLC6A4SLC6A2CYP3A4HTR2ACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2291 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387343-A1 | Nanoparticle Compositions and Methods for Synthesis Thereof | ICEUTICA PTY LTD (AU) | 2025-12-25 | — | — | US | claimed |
| WO-2025087695-A1 | METHOD FOR PRODUCING RECOMBINANT ADENO-ASSOCIATED VIRUS PARTICLES | ASCEND ADVANCED THERAPIES LTD (GB) | 2025-05-01 | — | — | WO | claimed |
| US-20240122855-A1 | Methods for the preparation of biologically active compounds in nanoparticulate form | ICEUTICA PTY LTD. (AU) | 2024-04-18 | — | — | US | claimed |
| US-20240016814-A1 | METHOD OF TREATING HYPERTENSION | CIPLA LIMITED (IN) | 2024-01-18 | — | — | US | claimed |
| US-20220054418-A1 | Methods for the preparation of biologically active compounds in nanoparticulate form | ICEUTICA PTY LTD. (AU) | 2022-02-24 | — | — | US | claimed |
| US-11033572-B2 | Molecular adjuvants for enhanced cytosolic delivery of active agents | UNIVERSITEIT GENT (BE) | 2021-06-15 | — | — | US | claimed |
| US-20200405729-A1 | METHOD OF TREATING HYPERTENSION | CIPLA LIMITED (IN) | 2020-12-31 | — | — | US | claimed |
| US-20200360294-A1 | Nanoparticle Compositions and Methods for Synthesis Thereof | ICEUTICA PTY LTD. (AU) | 2020-11-19 | — | — | US | claimed |
| EP-2054042-B1 | METHODS FOR THE PREPARATION OF BIOLOGICALLY ACTIVE COMPOUNDS IN NANOPARTICULATE FORM | ICEUTICA PTY LTD (AU) | 2020-04-29 | — | — | EP | claimed |
| US-20190328768-A1 | MOLECULAR ADJUVANTS FOR ENHANCED CYTOSOLIC DELIVERY OF ACTIVE AGENTS | UNIVERSITEIT GENT (BE) | 2019-10-31 | — | — | US | claimed |
| US-20030139698-A1 | Medicated wrap | HYSON MORTON I (US) | 2003-07-24 | — | — | US | claimed |
| EP-1309301-A1 | MEDICATED WRAP | Hyson, Morton I. (US) | 2003-05-14 | — | — | EP | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| US-20020035105-A1 | Composition and method combining an antidepressant with an NMDA receptor antagonist, for treating neuropathic pain | ENDO PHARMACEUTICALS INC. | 2002-03-21 | — | — | US | claimed |
| WO-2001080797-A1 | MEDICATED WRAP | HYSON MORTON I (US) | 2001-11-01 | — | — | WO | claimed |
| EP-0980247-A1 | COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR ANTAGONIST, FOR TREATING NEUROPATHIC PAIN | Algos Pharmaceutical Corporation (US) | 2000-02-23 | — | — | EP | claimed |
| WO-1998050044-A1 | COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR ANTAGONIST, FOR TREATING NEUROPATHIC PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |